0|chunk|Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
0	36	46 remdesivir	Chemical	CHEBI_145994
0	89	99 interferon	Chemical	CHEBI_52999
0	100	104 beta	Chemical	CHEBI_10545
0	CHEBI-CHEBI	CHEBI_145994	CHEBI_52999
0	CHEBI-CHEBI	CHEBI_145994	CHEBI_10545
0	CHEBI-CHEBI	CHEBI_52999	CHEBI_10545

1|chunk|Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human infections and over 851 deaths in 27 countries since 2012. There are no approved treatments for MERS-CoV infection although a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currently being evaluated in humans in the Kingdom of Saudi Arabia. Here, we show that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro. In mice, both prophylactic and therapeutic RDV improve pulmonary function and reduce lung viral loads and severe lung pathology. In contrast, prophylactic LPV/RTV-IFNb slightly reduces viral loads without impacting other disease parameters. Therapeutic LPV/RTV-IFNb improves pulmonary function but does not reduce virus replication or severe lung pathology. Thus, we provide in vivo evidence of the potential for RDV to treat MERS-CoV infections.
1	300	309 ritonavir	Chemical	CHEBI_45409
1	314	324 interferon	Chemical	CHEBI_52999
1	325	329 beta	Chemical	CHEBI_10545
1	435	445 remdesivir	Chemical	CHEBI_145994
1	475	484 antiviral	Chemical	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_45409	CHEBI_52999
1	CHEBI-CHEBI	CHEBI_45409	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_45409	CHEBI_145994
1	CHEBI-CHEBI	CHEBI_45409	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_10545
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_145994
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_10545	CHEBI_145994
1	CHEBI-CHEBI	CHEBI_10545	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_22587

